Regeneron's Arcalyst passes one gout trial, fails another
This article was originally published in Scrip
Executive Summary
Regeneron's biologic Arcalyst (rilonacept) – one of the world's most expensive therapies – met its primary endpoint in a Phase III trial for gout patients initiating allopurinol therapy, show top-line data from PRE-SURGE1. The company says it plans to file the interleukin-1 blocker, which is already been approved for the rare genetic variants of cryopyrin-associated periodic syndromes (CAPS), for gout mid-next year, pending the completion of two further trials.